POST-COVID-19 POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME
Clinical trials for POST-COVID-19 POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME explained in plain language.
Never miss a new study
Get alerted when new POST-COVID-19 POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME trials appear
Sign up with your email to follow new studies for POST-COVID-19 POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Hope dashed: drug trial for Post-COVID racing heart stopped early
Disease control TerminatedThis study tested a drug called IgPro20 (HIZENTRA) to see if it could help people with post-COVID POTS, a condition that causes a rapid heart rate and dizziness when standing. The trial was stopped early after enrolling only 16 adults. The goal was to see if the drug could reduce…
Matched conditions: POST-COVID-19 POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Experimental drug for Post-COVID POTS study halted early
Disease control TerminatedThis study looked at the long-term safety of efgartigimod in adults with post-COVID postural orthostatic tachycardia syndrome (POTS), a condition causing rapid heart rate and dizziness upon standing. The trial was an open-label extension for people who completed a previous study.…
Matched conditions: POST-COVID-19 POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME
Phase: PHASE2 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC